Two Phase 3 clinical trials testing pegozafermin in people with metabolic dysfunction-associated steatohepatitis (MASH), a severe manifestation of fatty…
Articles by Marisa Wexler, MS
The U.S. Food and Drug Administration (FDA) has given Gigagen the go-ahead to start clinical testing of GIGA-2339, its…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IN016, an experimental therapy Innorna is…
Pemvidutide, Altimmune’s experimental therapy, significantly reduced liver fat and inflammation, as well as body weight, among overweight or…
NGM Biopharmaceuticals has raised $122 million in financing, which the California-based company will use to help launch a planned…
The American Liver Foundation (ALF) has launched two projects that aim to improve care for people with metabolic…
Six months of treatment with a high dose of bexotegrast, Pliant Therapeutics’ oral candidate, was superior to a placebo…
Metabolic dysfunction-associated steatotic liver disease (MASLD), a form of fatty liver disease, and other aging-related metabolic disorders may be…
An initiative in the European Union (EU) aims to speed up the diagnosis of rare genetic disorders such as…
Global Fatty Liver Day, this year falling on June 13, is an annual effort to raise awareness about…